FunPep Company Limited (4881.T)
JPY 98.0
(-2.0%)
JPY 98.0
(-2.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.49 Billion JPY | -16.76% |
| 2022 | 2.99 Billion JPY | -11.06% |
| 2021 | 3.36 Billion JPY | -9.57% |
| 2020 | 3.72 Billion JPY | 265.96% |
| 2019 | 1.01 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 2.58 Billion JPY | 3.78% |
| 2024 Q2 | 2.68 Billion JPY | 3.98% |
| 2023 Q2 | 2.84 Billion JPY | -7.36% |
| 2023 FY | 2.49 Billion JPY | -16.76% |
| 2023 Q3 | 2.66 Billion JPY | -6.5% |
| 2023 Q4 | 2.49 Billion JPY | -6.5% |
| 2023 Q1 | 3.07 Billion JPY | 2.78% |
| 2022 Q3 | 2.8 Billion JPY | 0.0% |
| 2022 FY | 2.99 Billion JPY | -11.06% |
| 2022 Q4 | 2.99 Billion JPY | 6.81% |
| 2021 FY | 3.36 Billion JPY | -9.57% |
| 2020 FY | 3.72 Billion JPY | 265.96% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 62.194% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -105.636% |
| GNI Group Ltd. | 62.39 Billion JPY | 96.007% |
| Linical Co., Ltd. | 18.53 Billion JPY | 86.563% |
| Trans Genic Inc. | 9.81 Billion JPY | 74.609% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 55.785% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 64.136% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 57.17% |
| AnGes, Inc. | 28.89 Billion JPY | 91.378% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -187.237% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.415% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -53.908% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 50.878% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 42.731% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -2.395% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -4.962% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 64.054% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -42.232% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 51.015% |
| PeptiDream Inc. | 67.12 Billion JPY | 96.289% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -22.079% |
| Ribomic Inc. | 3.54 Billion JPY | 29.773% |
| SanBio Company Limited | 5.04 Billion JPY | 50.644% |
| Healios K.K. | 15.15 Billion JPY | 83.562% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -102.489% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 17.403% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -68.987% |
| StemRIM | 9.08 Billion JPY | 72.565% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 63.79% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 4.87% |
| Stella Pharma Corporation | 3.82 Billion JPY | 34.798% |
| TMS Co., Ltd. | 3.55 Billion JPY | 29.921% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 56.893% |
| Cuorips Inc. | 6.18 Billion JPY | 59.721% |
| K Pharma,Inc. | 3.31 Billion JPY | 24.828% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.978% |
| ReproCELL Incorporated | 9.05 Billion JPY | 72.482% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 8.256% |
| StemCell Institute Inc. | 6.54 Billion JPY | 61.927% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 64.355% |
| CellSeed Inc. | 2.46 Billion JPY | -1.029% |